zelavespib oral (PU-H71 oral) / Samus Therap - LARVOL DELTA

Phase I dose-escalation study of zelavespib in patients with relapsed myelofibrosis (YouTube) - "Gary Schiller, MD...outlines findings of a Phase I dose escalation study of the oral epichaperome inhibitor zelavespib in patients with relapsed myelofibrosis (MF; NCT03935555). Overall, the results demonstrated that zelavespib was well tolerated. Zelavespib has now been selected for a randomized Phase II trial which will investigate the therapeutic potential of the epichaperome inhibitor in combination with ruxolitinib in patients with relapsed MF. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA."

Interview • Video

Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib (clinicaltrials.gov) - P1b | N=11 | Terminated | Sponsor: Samus Therapeutics, Inc. | Completed ➔ Terminated; Samus Therapeutics company closure

Trial termination • Hematological Disorders • Myelofibrosis • Myeloproliferative Neoplasm • Polycythemia Vera • Thrombocytosis

Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib (clinicaltrials.gov) - P1b | N=11 | Completed | Sponsor: Samus Therapeutics, Inc. | Recruiting ➔ Completed | N=24 ➔ 11 | Trial completion date: May 2022 ➔ Nov 2022 | Trial primary completion date: May 2022 ➔ Oct 2022

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Hematological Disorders • Myelofibrosis • Myeloproliferative Neoplasm • Polycythemia Vera • Thrombocytosis

Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib (clinicaltrials.gov) - P1b; N=24; Recruiting; Sponsor: Samus Therapeutics, Inc.; Trial completion date: May 2021 ➔ May 2022; Trial primary completion date: May 2021 ➔ May 2022

Trial completion date • Trial primary completion date • Hematological Disorders • Myelofibrosis • Myeloproliferative Neoplasm • Polycythemia Vera • Thrombocytosis